Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma.

ABSTRACT: Chimeric antigen receptor (CAR) cell-based therapies have demonstrated limited success in solid tumors, including glioblastoma (GBM). GBMs exhibit high heterogeneity and create an immunosuppressive tumor microenvironment (TME). In addition, other challenges exist for CAR therapy, including trafficking and infiltration into the tumor site, proliferation, persistence of CARs once in the tumor, and reduced functionality, such as suboptimal cytokine production. Cytokine modification is of interest, as one can enhance therapy efficacy and minimize off-target toxicity by directly combining CAR therapy with cytokines, antibodies, or oncolytic viruses that alter cytokine response pathways. Alternatively, one can genetically modify CAR T-cells or CAR NK-cells to secrete cytokines or express cytokin

SUBMITTER: Pawlowski KD 

PROVIDER: S-EPMC10741789 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature